- Conditions
- Coronary Artery Disease
- Interventions
- Edoxaban 60 mg, Edoxaban 30 mg, Clopidogrel 75 mg, Aspirin 81 mg
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Atrial Fibrillation
- Interventions
- Edoxaban, Warfarin, Enoxaparin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Escondido, California • Newport Beach, California + 25 more
- Conditions
- Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
- Interventions
- Edoxaban, Standard of Care
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 1 Day to 17 Years
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more
- Conditions
- Cardiac Disease
- Interventions
- Edoxaban, Standard of Care (SOC)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 1 Day to 17 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 10 more
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
- Interventions
- Edoxaban, Dalteparin, Low molecular weight heparin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,046 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Brandon, Florida • Jonesboro, Georgia • Detroit, Michigan + 1 more
- Conditions
- Stroke, Atrial Fibrillation
- Interventions
- Non-vitamin K oral anticoagulant (NOAC)
- Drug
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 2,270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas
- Conditions
- Peripheral Arterial Disease
- Interventions
- edoxaban, Clopidogrel, Aspirin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 23 more
- Conditions
- Atrial Fibrillation
- Interventions
- Edoxaban-based Regimen, VKA-based Regimen
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 60 more
- Conditions
- Intracranial Hemorrhages, Atrial Fibrillation
- Interventions
- Edoxaban, Non-anticoagulant medical therapy
- Drug · Other
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 948 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 10
- States / cities
- Elk Grove Village, Illinois • Lisle, Illinois • New Orleans, Louisiana + 7 more
- Conditions
- Healthy
- Interventions
- PER977, Placebo, enoxaparin
- Drug
- Lead sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Atrial Fibrillation
- Interventions
- Edoxaban, Warfarin
- Drug
- Lead sponsor
- Electrophysiology Research Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Warren Township, New Jersey
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism, Venous Thrombosis
- Interventions
- edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8,292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 82
- States / cities
- Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 71 more